In order to determine the therapeutic potential of targeting miR-29a or AKT signaling in treatment of breast cancer, a kind of magnetic nanoparticles carrying miR-29a inhibitor was applied to treat the TNBC tumor-burden mice. The gene discussed is AKT1; the disease is breast carcinoma.